MDA - Market Direction Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : MDA - Market Direction Analysis

SPY 670.92

+0.1%

Nov 7 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Haim R. Branisteanu who wrote (55397)	6/26/2000 9:55:00 PM
From: Casaubon	Read Replies (3) of 99985

Haim, It used to be that big pharma rammed mediocre compounds through the clinic. Now that truly innovative drugs which really work are being designed, the flaws in the old crap get highlighted. Big pharma keeps loosing market share to upstart biotech, so the only thing they can do to stay in business is buy their pipelines. How many times have you seen old compounds pulled from the shelves due to some "previously unknown" toxic side effect. The new crop of drugs is less error prone as the compounds are specifically designed against a protein or foreign invader (bacterial or viral). The specificity increases the odds of success and diminishes the potential for toxicity complications. The FDA is streamlining and better trial designs allow for more meaningful clinical endpoints.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next